May 17, 2020

mHealth-As-A-Service Could Change Mobile Health

2 min
mHaaS Could Move Healthcare To The Cloud
Software-as-a-service (SaaS) when it comes to cloud computing is often talked about, but what about mobile healthcare-as-a-service (mHaaS)? In a recen...


Software-as-a-service (SaaS) when it comes to cloud computing is often talked about, but what about mobile healthcare-as-a-service (mHaaS)? In a recent article, written by John Sung Kim, CEO of San Francisco based and published in PhysBizTech, the case is made that mHealth apps for medical provider organizations will soon evolve into app platforms whose functions can be ‘rented’ as a cloud-based service instead of building them as ‘one-off’ IT projects. Sung Kim goes on to say that mHaaS is the only way the mHealth industry will grow.

Sung Kim, who runs a mobile healthcare 2.0 company, believes the benefit of mHaaS is that it significantly decreases the costs and risks for medical provider organizations.

“Singularly built medical apps may suffice for certain tools such as drug reference information, but apps such as patient communications or mobile medical consultations require systems built on a multi-tenant architecture with the capability to scale and become extensible by third parties through application programming interfaces,” says Sung Kim, adding that “mHaaS is not only coming - it's the only viable way our industry will grow.”

Sung Kim says that mHaaS is an obvious pathway for mHealth provision. All one has to do is look at the cost and pricing structure of mHaaS versus building them internally as standalone apps, he says. He estimates the total first year cost to provider organizations for in-house or outsourced application development for a single app to be $181,000, while the total first year cost with mHaaS falls significantly to $18,000 ($1,500 per month in subscription fees to access and deploy a cloud-based mHealth app as a rented service with 1,000 customers on its mHaaS platform).

“In the current landscape of mHealth applications launched by medical provider organizations, there is much anecdotal evidence that suggests most of these initiatives fail to achieve their originally stated performance and cost objectives,” Sung Kim concludes. “Fortunately, the money and math add up quite nicely for those who can execute on the approaching mHaaS future.”

Share article

Jun 18, 2021

Skin Analytics wins NHSX award for AI skin cancer tool 

2 min
Skin Analytics uses AI to detect skin cancer and will be deployed across the NHS to ease patient backlogs

An artificial intelligence-driven tool that identifies skin cancers has received an award from NHSX, the NHS England and Department of Health and Social Care's initiative to bring technology into the UK's national health system. 

NHSX has granted the Artificial Intelligence in Health and Care Award to DERM, an AI solution that can identify 11 types of skin lesion. 

Developed by Skin Analytics, DERM analyses images of skin lesions using algorithms. Within primary care, Skin Analytics will be used as an additional tool to help doctors with their decision making. 

In secondary care, it enables AI telehealth hubs to support dermatologists with triage, directing patients to the right next step. This will help speed up diagnosis, and patients with benign skin lesions can be identified earlier, redirecting them away from dermatology departments that are at full capacity due to the COVID-19 backlog. 

Cancer Research has called the impact of the pandemic on cancer services "devastating", with a 42% drop in the number of people starting cancer treatment after screening. 

DERM is already in use at University Hospitals Birmingham and Mid and South Essex Health & Care Partnership, where it has led to a significant reduction in unnecessary referrals to hospital.

Now NHSX have granted it the Phase 4 AI in Health and Care Award, making DERM available to clinicians across the country. Overall this award makes £140 million available over four years to accelerate the use of artificial intelligence technologies which meet the aims of the NHS Long Term Plan.

Dr Lucy Thomas, Consultant Dermatologist at Chelsea & Westminster Hospital, said: “Skin Analytics’ receipt of this award is great news for the NHS and dermatology departments. It will allow us to gather real-world data to demonstrate the benefits of AI on patient pathways and workforce challenges. 

"Like many services, dermatology has severe backlogs due to the COVID-19 pandemic. This award couldn't have come at a better time to aid recovery and give us more time with the patients most in need of our help.”

Share article